Policies

Shareholder Policy in Hofseth BioCare ASA

All shares in Hofseth Biocare are freely negotiable.

Hofseth BioCare has only one class of shares.

At capital increases all shareholders shall be treated equally as far as possible. If an unequal treatment should occur, remaining shareholders shall by consecutive measurements be offered a position as if they were included in the original capital increase.

Transactions in the corporations own shares shall normally be negotiated over the stock exchange or at last market price.

Special caution is required for transactions where shareholders, board members, management or any closely related of the former have any financial or personal interest.

In the case of any significant transactions where shareholders, board members, management or any closely related of the former have any financial or personal interests, an independent third party evaluation shall exist.


Investor Relation policy

Hofseth BioCare complies with The Oslo Børs’ Code of Practice for Reporting IR Information.

Hofseth BioCare’s information policy is based on openness and equal treatment of all shareholders. Hofseth BioCare strives to continuously publish all relevant information to the market in a timely, effective and non-discriminatory manner. All stock exchange announcements are made available both on the Company’s website and on the Oslo Stock Exchange news website www.newsweb.no and are also distributed to news agencies (via GlobalNewswire).

The Company publishes its preliminary annual financial statements by the end of February, together with its fourth quarter results.

The complete annual report and financial statements are made available to shareholders no later than three weeks prior to the annual general meeting, or, at the latest, by 30 April each year, which is the last date permitted by the Securities Trading Act.

Quarterly preliminary reports are normally published at the latest within two months after the close of the quarter.

The Company’s financial calendar for the coming year is published no later than December 31 in accordance with the rules of the Oslo Stock Exchange. The financial calendar is available on the company’s website and on the Oslo Stock Exchange website. Quarterly reports and presentation material are available on the Company’s website, www.hofsethbiocare.com.

Contact IR

James Berger
James Berger
Head of Investor Relations & Strategy
+41 79 950 10 34 jb@hofsethbiocare.no
Crawford Currie
Dr. Crawford Currie
Medical R&D & Investor Relations
+44 7968 195497 cc@hofsethbiocare.no